Under construction – not a live service
Sign in
Taking people in SpainNo phase

Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients

Key facts

Where
Oviedo and Valladolid, SpainSee the 2 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 65 and 75 years old?

Source: NCT06861361, who can take part

Where in Spain

  • Hospital Universitario Central De AsturiasOviedo, SpainContact: Pablo Avanzas, MDTaking people
  • Hospital Clínico Universitario de ValladolidValladolid, SpainContact: Ignacio Amat Santos, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Ceric Sàrl
Trial code
NCT06861361
Record updated
12 May 2026
Original description
The study objective is to demonstrate that the clinical outcomes of the Myval balloon-expandable THV series are non-inferior to those of SAVR in patients with symptomatic severe aortic stenosis aged 65 to 75 years.Read full original descriptionShow less

Surgical Bioprosthesis Aortic Valve Replacement Vs. Myval Balloon-Expandable THV Series in Patients Aged 65 to 75 With Symptomatic Severe Aortic Stenosis Judged Eligible by Heart Team

The study objective is to demonstrate that the clinical outcomes of the Myval balloon-expandable THV series are non-inferior to those of SAVR in patients with symptomatic severe aortic stenosis aged 65 to 75 years.

Inclusion: Participant will be included if all the following criteria are met:; Patients aged ≥65 and ≤75; Symptomatic severe aortic stenosis (mean gradient≥40mmHg, and or peak velocity>4m/sec); Patients with symptomatic heart disease due to severe native calcific aortic stenosis, as judged by a multidisciplinary heart team (including a cardiac surgeon), for whom SAVR or transfemoral TAVR is deemed feasible and approved by the local heart team.Signed informed consent for participation in the clinical investigation.

Exclusion: Participant will not be included if any one of the following conditions exists:; Known hypersensitivity or allergy to aspirin, clopidogrel or any Device frame components; Unable to understand and follow clinical investigation-related instructions or unable to comply with the clinical investigation protocol; Life expectancy less than 1 year; Under judicial protection, tutorship, or curatorship; Participation in another trial before the primary endpoint.

ClinicalTrials.gov NCT06861361